Analysis of predictive and preventive factors for de Novo DSA in kidney transplant recipients

Transplantation

Volumn 98, Issue 4, 2014, Pages 443-450

  Hirai, Toshihito ^a   Furusawa, Miyuki ^a   Omoto, Kazuya ^a   Ishida, Hideki ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

De novo DSA; Kidney transplantation; Rituximab; Single antigen bead assay

Indexed keywords

DONOR SPECIFIC HLA ANTIBODY; HLA ANTIBODY; HLA DR ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; RETROSPECTIVE STUDY; SINGLE ANTIGEN BEAD ASSAY; SURVIVAL RATE; AGED; BLOOD; DONOR; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84907972116     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000071     Document Type: Article

References (40)

1. Martin S, Dyer PA, Mallick NP, et al. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50.
2. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
3. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532.
4. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
5. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
6. Li X, Ishida H, Yamaguchi Y, et al. Poor graft outcome in recipients withde novodonor-specific anti-HLA antibodies after living related kidney transplantation. Transplant International 2008; 21: 1145.
7. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
8. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
9. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
10. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttrans-plant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
11. Cooper JE, Gralla J, Cagle L, et al. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103.
12. Ntokou I-SA, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transplant Int 2011; 24: 1084.
13. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novodonor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012; 12: 3355.
14. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
15. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplant J 2013; 95: 410.
16. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
17. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864.
18. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplant J 2013; 95: 19.
19. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
20. Kaneku H, O'Leary JG, Banuelos N, et al. De novodonor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541.
21. Hirai T, Kohei N, Omoto K, et al. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012; 25: 925.
22. Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
23. Hirai T, Ishida H, Toki D, et al. Comparison of the acute rejection incidence rate in spousal donor transplantation before and after anti-CD20 antibody (rituximab) protocol as desensitization therapy. Ther Apher Dial 2010; 15: 89.
24. Takagi T, Ishida H, Shirakawa H, et al. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
25. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplantation 2009; 9: 1099.
26. Billing H, Rieger S, Süsal C, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediat-ric renal transplantation with a 2-year follow-up. Transplant Int 2012; 25: 1165.
27. Takagi T, Ishida H, Shirakawa H, et al. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transplant Immunology 2010; 23: 220.
28. Samaniego M, Mezrich J, Torrealba J, et al. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience. Clin Transpl 2006: 503.
29. Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23: 390.
30. Thaunat O, Hanf W, Dubois V, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloanti-bodies generation. Transpl Immunol 2009; 20: 209.
31. Singh P, Colombe BW, Francos GC, et al. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation 2010; 90: 220.
32. Gilbert M, Paul S, Perrat G, et al. Impact of pretransplant human leukocyte antigen-C and-DP antibodies on kidney graft outcome. Transplant Proc 2011; 43: 3412.
33. Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-a strategy to minimizede novodonor-specific antibody development and improve outcomes. Am J Transplant 2013; 13: 3114.
34. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplant J 2012; 94: 172.
35. Nakajima F, Nakamura J, Yokota T. Analysis of HLA haplotypes in Japanease, using high resolution allele typing. MHC 2001; 8: 1.
36. Aubert V, Venetz JP, Pantaleo G, et al. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009; 70: 580.
37. Smith RN, Kawai T, Boskovic S, et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662.
38. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients withde novodonor-specific antibodies. Am J Transplant 2013; 13: 485.
39. Ishida H, Tanabe K, Tokumoto T, et al. The evaluation of graft irradiation as a method of preventing hemolysis after ABO-mismatched renal transplantation. Transpl Int 2002; 15: 421.
40. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9: 567.